Journal article
Cardiovascular Safety of Inhaled Long-Acting Bronchodilators in Individuals With Chronic Obstructive Pulmonary Disease
Abstract
IMPORTANCE: Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. Long-acting inhaled β-agonists and anticholinergics, first-line medications for COPD, have been associated with increased risk of cardiovascular outcomes. When choosing between the medications, patients and physicians would benefit from knowing which has the least risk.
OBJECTIVE: To assess the association of these classes of medications with the risk of …
Authors
Gershon A; Croxford R; Calzavara A; To T; Stanbrook MB; Upshur R; Stukel TA
Journal
JAMA Internal Medicine, Vol. 173, No. 13, pp. 1175–1185
Publisher
American Medical Association (AMA)
Publication Date
July 8, 2013
DOI
10.1001/jamainternmed.2013.1016
ISSN
2168-6106
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Administration, InhalationAgedBronchodilator AgentsCase-Control StudiesCholinergic AntagonistsCohort StudiesFemaleHeart FailureHumansMaleMonitoring, PhysiologicOntarioPulmonary Disease, Chronic ObstructiveRetrospective StudiesRisk AssessmentRisk FactorsScopolamine DerivativesTiotropium BromideTreatment Outcome